메뉴 건너뛰기




Volumn 54, Issue 1, 2012, Pages 1-9

Hepatitis C virus infection management in 2012

Author keywords

Antiviral agents ; Hepatitis C ; Protease inhibitors ribavirin

Indexed keywords

ANTIVIRUS AGENT;

EID: 84858807715     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (5)

References (68)
  • 1
    • 59149085501 scopus 로고    scopus 로고
    • The global burden of hepatitis C
    • Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81.
    • (2009) Liver Int , vol.29 , Issue.SUPPL. 1 , pp. 74-81
    • Lavanchy, D.1
  • 3
    • 65449136656 scopus 로고    scopus 로고
    • American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update
    • Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Seeff, L.B.1
  • 4
    • 78650803266 scopus 로고    scopus 로고
    • HCV RESPOND-2 final results: High sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus pegintron/ribavirin
    • Bacon BR, Bruno S, Manns MP, Sulkowski MS. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus pegintron/ribavirin. Hepatology 2010;52:430A.
    • (2010) Hepatology , vol.52
    • Bacon, B.R.1    Bruno, S.2    Manns, M.P.3    Sulkowski, M.S.4
  • 5
    • 78650820415 scopus 로고    scopus 로고
    • Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: Final results of phase 3 ADVANCE study
    • Jacobson IM. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. Hepatology 2010;52(427A).
    • (2010) Hepatology , vol.52 , Issue.427
    • Jacobson, I.M.1
  • 6
    • 78650806148 scopus 로고    scopus 로고
    • Boceprevir (BOC) combined with peginterferon alfa-2b/ ribavirin (P/R) for treatment-naive patients with hepatitis C (HCV) genotype 1: SPRINT-2 final results
    • Poordad F. Boceprevir (BOC) combined with peginterferon alfa-2b/ ribavirin (P/R) for treatment-naive patients with hepatitis C (HCV) genotype 1: SPRINT-2 final results. Hepatology 2010;52(402A).
    • (2010) Hepatology , vol.52 , Issue.402
    • Poordad, F.1
  • 7
    • 78751626981 scopus 로고    scopus 로고
    • Telaprevir in combination with peginterferon alfa2b and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: Final results of phase 3 ILLUMINATE study
    • Sherman KE. Telaprevir in combination with peginterferon alfa2b and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010;52(401A).
    • (2010) Hepatology , vol.52 , Issue.401
    • Sherman, K.E.1
  • 8
    • 79960453276 scopus 로고    scopus 로고
    • Management of hepatitis C virus infection
    • EASL Clinical Practice Guidelines
    • EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
    • (2011) J Hepatol , vol.55 , pp. 245-264
  • 9
    • 23944506014 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis C virus infection
    • DOI 10.1016/S1473-3099(05)70216-4, PII S1473309905702164
    • Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67. (Pubitemid 41196755)
    • (2005) Lancet Infectious Diseases , vol.5 , Issue.9 , pp. 558-567
    • Shepard, C.W.1    Finelli, L.2    Alter, M.J.3
  • 10
    • 36549067746 scopus 로고    scopus 로고
    • The changing epidemiology of hepatitis C virus infection in Europe
    • DOI 10.1016/j.jhep.2007.07.033, PII S0168827807005739
    • Esteban JL, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-62. (Pubitemid 350191999)
    • (2008) Journal of Hepatology , vol.48 , Issue.1 , pp. 148-162
    • Esteban, J.I.1    Sauleda, S.2    Quer, J.3
  • 11
    • 0035056914 scopus 로고    scopus 로고
    • Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus
    • European Paediatric Hepatitis C Virus Network
    • European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001;108:371-7.
    • (2001) European Paediatric Hepatitis C Virus Network. BJOG , vol.108 , pp. 371-377
  • 13
    • 0019948091 scopus 로고
    • Sporadic non-A, non-B hepatitis: Frequency and epidemiology in an urban U.S. population
    • Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93. (Pubitemid 12088968)
    • (1982) Journal of Infectious Diseases , vol.145 , Issue.6 , pp. 886-893
    • Alter, M.J.1    Gerety, R.J.2    Smallwood, L.A.3
  • 15
    • 78751621217 scopus 로고    scopus 로고
    • Evolving epidemiology of hepatitis C virus
    • Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011:17:107-15.
    • (2011) Clin Microbiol Infect , vol.17 , pp. 107-115
    • Lavanchy, D.1
  • 16
    • 77950624760 scopus 로고    scopus 로고
    • The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report
    • Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-55.
    • (2010) Liver Int , vol.30 , pp. 342-355
    • Antaki, N.1    Craxi, A.2    Kamal, S.3    Moucari, R.4    Van Der Merwe, S.5    Haffar, S.6
  • 17
    • 77958029477 scopus 로고    scopus 로고
    • Practice guidelines for the treatment of hepatitis C
    • recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting
    • Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010;42:81-91.
    • (2010) Dig Liver Dis , vol.42 , pp. 81-91
  • 19
    • 34247216563 scopus 로고    scopus 로고
    • Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection
    • Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party
    • Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33.
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 615-633
    • McCaughan, G.W.1    Omata, M.2    Amarapurkar, D.3    Bowden, S.4    Chow, W.C.5
  • 20
    • 72249094116 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
    • Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-22.
    • (2010) Gastroenterology , vol.138 , pp. 116-122
    • Ascione, A.1    De Luca, M.2    Tartaglione, M.T.3    Lampasi, F.4    Di Costanzo, G.G.5    Lanza, A.G.6
  • 22
    • 72249083270 scopus 로고    scopus 로고
    • Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    • Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15.
    • (2010) Gastroenterology , vol.138 , pp. 108-115
    • Rumi, M.G.1    Aghemo, A.2    Prati, G.M.3    D'Ambrosio, R.4    Donato, M.F.5    Soffredini, R.6
  • 23
    • 0033919083 scopus 로고    scopus 로고
    • Adverse effects and other safety aspects of the hepatitis C antivirals
    • DOI 10.1046/j.1440-1746.2000.02114.x
    • Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000;15(Suppl):E156-63. (Pubitemid 30435754)
    • (2000) Journal of Gastroenterology and Hepatology , vol.15 , Issue.SUPPL. MAY
    • Chutaputti, A.1
  • 25
    • 77949320438 scopus 로고    scopus 로고
    • Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: A review of the literature
    • Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010;55:579-85.
    • (2010) Dig Dis Sci , vol.55 , pp. 579-585
    • Slavenburg, S.1    Heijdra, Y.F.2    Drenth, J.P.3
  • 26
    • 1842463813 scopus 로고    scopus 로고
    • Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection
    • DOI 10.1111/j.1365-2893.2004.00490.x
    • Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50. (Pubitemid 38658449)
    • (2004) Journal of Viral Hepatitis , vol.11 , Issue.3 , pp. 243-250
    • Sulkowski, M.S.1    Wasserman, R.2    Brooks, L.3    Ball, L.4    Gish, R.5
  • 27
    • 75649147072 scopus 로고    scopus 로고
    • Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag
    • Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J Gastroenterol 2010;16:51-6.
    • (2010) Saudi J Gastroenterol , vol.16 , pp. 51-56
    • Danish, F.A.1    Koul, S.S.2    Subhani, F.R.3    Rabbani, A.E.4    Yasmin, S.5
  • 28
    • 81355148539 scopus 로고    scopus 로고
    • Randomised clinical trial: Escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C
    • de Knegt RJ, Bezemer G, Van Gool AR, Drenth JP, Hansen BE, Droogleever Fortuyn HA et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011;34:1306-17.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 1306-1317
    • De Knegt, R.J.1    Bezemer, G.2    Van Gool, A.R.3    Drenth, J.P.4    Hansen, B.E.5    Droogleever Fortuyn, H.A.6
  • 30
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5    Marcellin, P.6
  • 31
  • 33
    • 80052024078 scopus 로고    scopus 로고
    • Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future
    • Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011;54:789-800.
    • (2011) Hepatology , vol.54 , pp. 789-800
    • Di Martino, V.1    Richou, C.2    Cervoni, J.P.3    Sanchez-Tapias, J.M.4    Jensen, D.M.5    Mangia, A.6
  • 34
    • 79961234860 scopus 로고    scopus 로고
    • Treatment extension benefits HCV genotype 1 patients without rapid virological response: A systematic review
    • Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med 2011;69:216-21.
    • (2011) Neth J Med , vol.69 , pp. 216-221
    • Gevers, T.J.1    Slavenburg, S.2    Van Oijen, M.G.3    Drenth, J.P.4
  • 35
    • 62149105964 scopus 로고    scopus 로고
    • A study of best positive predictors for sustained virologie response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients
    • Idrees M, Riazuddin S. A study of best positive predictors for sustained virologie response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5.
    • (2009) BMC Gastroenterol , vol.9 , pp. 5
    • Idrees, M.1    Riazuddin, S.2
  • 36
    • 34547428001 scopus 로고    scopus 로고
    • Predictors of response of U.S. veterans to treatment for the hepatitis C virus
    • DOI 10.1002/hep.21662
    • Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47. (Pubitemid 47171919)
    • (2007) Hepatology , vol.46 , Issue.1 , pp. 37-47
    • Backus, L.I.1    Boothroyd, D.B.2    Phillips, B.R.3    Mole, L.A.4
  • 39
    • 53049096125 scopus 로고    scopus 로고
    • Predictors of SVR in naive HCV G1 patients in real life practice: The PROBE
    • Suppl 2
    • Craxi A et al. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE. J Hepatol 2008;48(Suppl 2):S291.
    • (2008) J Hepatol , vol.48
    • Craxi, A.1
  • 41
    • 11144358311 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    • discussion 947
    • Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23; discussion 947.
    • (2004) Gastroenterology , vol.126 , pp. 1015-1023
    • Shiffman, M.L.1    Di Bisceglie, A.M.2    Lindsay, K.L.3    Morishima, C.4    Wright, E.C.5    Everson, G.T.6
  • 43
    • 70349292099 scopus 로고    scopus 로고
    • Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance
    • Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009;461:399-401.
    • (2009) Nature , vol.461 , pp. 399-401
    • Ge, D.1    Fellay, J.2    Thompson, A.J.3    Simon, J.S.4    Shianna, K.V.5    Urban, T.J.6
  • 44
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    • Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
    • (2009) Nat Genet , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3    Berg, T.4    Weltman, M.5    Abate, M.L.6
  • 45
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
    • (2009) Nat Genet , vol.41 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3    Kurosaki, M.4    Matsuura, K.5    Sakamoto, N.6
  • 47
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    • DOI 10.1053/jhep.2003.50364
    • Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologie response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52. (Pubitemid 37052151)
    • (2003) Hepatology , vol.38 , Issue.3 , pp. 645-652
    • Davis, G.L.1    Wong, J.B.2    McHutchison, J.G.3    Manns, M.P.4    Harvey, J.5    Albrecht, J.6
  • 50
    • 34249040959 scopus 로고    scopus 로고
    • The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1
    • Barcena R, Moreno A, del Campo S, Muriel A, Mateos ML, Garrido E et al. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1. Antivir Ther 2007; 12:401 -6.
    • (2007) Antivir Ther , vol.12 , pp. 401-406
    • Barcena, R.1    Moreno, A.2    Del Campo, S.3    Muriel, A.4    Mateos, M.L.5    Garrido, E.6
  • 52
    • 54449089071 scopus 로고    scopus 로고
    • Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon alpha-2a and ribavirin
    • Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008;48:1033-43.
    • (2008) Hepatology , vol.48 , pp. 1033-1043
    • Fried, M.W.1    Jensen, D.M.2    Rodriguez-Torres, M.3    Nyberg, L.M.4    Di Bisceglie, A.M.5    Morgan, T.R.6
  • 55
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • DOI 10.1016/j.jhep.2005.10.003, PII S0168827805006677
    • Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103. (Pubitemid 41772522)
    • (2006) Journal of Hepatology , vol.44 , Issue.1 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3    Sperl, J.4    Horsmans, Y.5    Cianciara, J.6    Ibranyi, E.7    Weiland, O.8    Noviello, S.9    Brass, C.10    Albrecht, J.11
  • 56
    • 79958816097 scopus 로고    scopus 로고
    • Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
    • Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011;55:69-75.
    • (2011) J Hepatol , vol.55 , pp. 69-75
    • Fried, M.W.1    Hadziyannis, S.J.2    Shiffman, M.L.3    Messinger, D.4    Zeuzem, S.5
  • 57
    • 77749341043 scopus 로고    scopus 로고
    • The German guidelines on the management of HCV infection
    • Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection
    • Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U et al. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010;48:289-351.
    • (2010) Z Gastroenterol , vol.48 , pp. 289-351
    • Sarrazin, C.1    Berg, T.2    Ross, R.S.3    Schirmacher, P.4    Wedemeyer, H.5    Neumann, U.6
  • 58
    • 0036788338 scopus 로고    scopus 로고
    • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    • McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
    • (2002) Gastroenterology , vol.123 , pp. 1061-1069
    • McHutchison, J.G.1    Manns, M.2    Patel, K.3    Poynard, T.4    Lindsay, K.L.5    Trepo, C.6
  • 59
    • 77957233758 scopus 로고    scopus 로고
    • Meta-analysis: Re-treatment of genotype i hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
    • Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010;32:969-83.
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 969-983
    • Singal, A.G.1    Waljee, A.K.2    Shiffman, M.3    Bacon, B.R.4    Schoenfeld, P.S.5
  • 62
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson, I.M., et al., Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011-,364:2405-16.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1
  • 66
    • 79251554986 scopus 로고    scopus 로고
    • Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C
    • e1; quiz e14
    • Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68 e1; quiz e14.
    • (2011) Gastroenterology , vol.140 , pp. 459-468
    • Marcellin, P.1    Forns, X.2    Goeser, T.3    Ferenci, P.4    Nevens, F.5    Carosi, G.6
  • 67
    • 0034720668 scopus 로고    scopus 로고
    • Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV)
    • Schvarcz R, Rudbeck G, Söderdahl G, Ståhle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69:2194-5. (Pubitemid 30395060)
    • (2000) Transplantation , vol.69 , Issue.10 , pp. 2194-2195
    • Schvarcz, R.1    Rudbeck, G.2    Soderdahl, G.3    Stahle, L.4
  • 68
    • 84862907480 scopus 로고    scopus 로고
    • Synthesis of stable isotope labeled analogs of the anti-hepatitis c virus nucleotide prodrugs psi-7977 and psi-352938
    • Chun BK, Du J, Zhang HR, Chang W, Ross BS, Jiang Y et al. Synthesis of Stable Isotope Labeled Analogs of the Anti-Hepatitis C Virus Nucleotide Prodrugs PSI-7977 and PSI-352938. Nucleosides Nucleotides Nucleic Acids 2011;30:886-96.
    • (2011) Nucleosides Nucleotides Nucleic Acids , vol.30 , pp. 886-896
    • Chun, B.K.1    Du, J.2    Zhang, H.R.3    Chang, W.4    Ross, B.S.5    Jiang, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.